Alvimopan
Peripheral Opioid Receptor Antagonists
- Drug class
- Peripheral Opioid Receptor Antagonists
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 1
- Products on record
- 1
- FDA reports (12 mo)
- 1
Overview
Plain-language summary, compiled from the cited regulatory records
Alvimopan is a medication classified as a peripheral opioid receptor antagonist [1]. It is approved to accelerate the time to upper and lower gastrointestinal recovery after surgeries that involve a partial bowel resection with a primary anastomosis [1].
This medication is available under various brand names [N]. In the past 12 months, there has been 1 adverse event report associated with alvimopan [2]. The most frequently reported adverse reactions include abdominal distension, abdominal pain, and intestinal obstruction [2]. Other reported reactions include myocardial infarction and absent pulse [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| US United States | FDA | 1 | February 8, 2024 |
USUnited States· FDA
1 product
Uses
1 INDICATIONS AND USAGE Alvimopan capsules are indicated to accelerate the time to upper and lower gastrointestinal recovery following surgeries that include partial bowel resection with primary anastomosis. Alvimopan capsules are an opioid antagonist indicated to accelerate the time to upper and lower gastrointestinal recovery following surgeries that include partial bowel resection with primary anastomosis.
( 1 )
How to take
Drug interactions
Known interactions involving Alvimopan. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]FDA DailyMed · 10e39d3b-8621-16… · revised February 8, 2024 [PDF]
- [2]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.